Weiliang Xia, Ph.D., is tenured full professor at School of Biomedical Engineering and Associate Dean of Zhiyuan College (an Honors College) at Shanghai Jiao Tong University. He obtained his doctoral degree from the University of Hong Kong with predoctoral training at the Rockefeller University from 2003 to 2006, followed by a postdoctoral training at UCSF from 2007 to 2008. The research interest of his group includes mechanisms of cancer progression, treatment resistance and theranostic target identification, exosome biology and application, roles of FGF/FGFR signaling and sirtuins in cancer progression and tissue repair. Dr. Xia has published more than 130 research papers, with an H-index of 50. He is Associate Editor for Extracellular Vesicles and Circulating Nucleic Acids(EVCNA).  He has been awarded the Rising Star Prize by Shanghai Science and Technology Commission, Tang Lixin Young Faculty Award of SJTU, and Chinese Medical Science & Technology Award in 2021.

2002-2006 PhD in Molecular and Cell Biology, The University of Hong Kong with joint pre-doctoral program at The Rockefeller University

1999-2002 BSc in Biotechnology, The University of Hong Kong

1998-1999 Enrolled and studied in the BSc Program in Biology and Biotechnology，Dept. of Biological Science and Biotechnology, Tsinghua University

2014-present Professor, School of Biomedical Engineering, Shanghai Jiao Tong University

2012-2014 Special Investigator (Tenure-track Associate Professor), School of Biomedical Engineering, Shanghai Jiao Tong University

2008-2011 Associate Professor, Med-X Research Institute, Shanghai Jiao Tong University 

2007-2008 Postdoctoral Associates, University of California at San Francisco

Mechanisms of lung/prostate cancer progression and treatment resistance, and discovery of novel targets; biology of exosome and applications; role of FGF/FGFR and sirtuin in cancer and tissue repair.

"Rising Star" Award (2009), Science and Technology Commission of Shanghai

SMC Award (2009), Shanghai Jiao Tong University

First Prize in Teaching Achievement (2013), Shanghai Jiao Tong University

Second Prize in Teaching Achievement (2013), Shanghai Municipality

Tang Lixin Scholar (2018), Shanghai Jiao Tong University

Grand Prize in Teaching Achievement (2020), Shanghai Jiao Tong University

Associate Editor, Extracellular Vesicles and Circulating Nucleic Acids

Member, American Association for Cancer Research; 

Member, Chinese Cell Biology Society; 

Member, Chinese Biomedical Engineering Society.

Cell Biology, BME2402 (Spring, School of Biomedical Engineering)

Cell Biology, BIO3350 (Autumn, honors course for Zhiyuan College)

Cell Biology Tutorials, BIO3351 (Autumn, Zhiyuan College)

ZIRC Exploratory Laboratory Course, ZYH1301 (Autumn/Spring, Zhiyuan College)

1. Chen Z, Ji W, Feng W, Cui J, Wang Y, Li F, Chen J, Guo Z, Xia L, Zhu X, Niu X, Zhang Y, Li Z, Wong AS, Lu S*, Xia W*. PTPRT loss enhances anti-PD-1 therapy efficacy by regulation of STING pathway in non-small cell lung cancer. Sci Transl Med. 2024 Sep 4;16(763):eadl3598. doi: 10.1126/scitranslmed.adl3598.
2. Wu T, Zhang Y, Han Q, Lu X, Cheng Y, Chen J, Sha J, Xia W*. Klotho-beta attenuates Rab8a-mediated exosome regulation and promotes prostate cancer progression. Oncogene. 2023;42:2801-2815.
3. Zhang Y, Wu T, Wang Y, Chen Z, Chen J, Lu S, Xia W*. Reciprocal FGF19-GLI2 signaling induces epithelial-to-mesenchymal transition to promote lung squamous cell carcinoma metastasis. Cell Oncol. 2023;46:437-450.
4. Tian A, Wu T, Zhang Y, Chen J, Sha J, Xia W*. Triggering pyroptosis enhances the antitumor efficacy of PARP inhibitors in prostate cancer. Cell Oncol. 2023;46:1855-1870.
5. Lu X, Han Q, Chen J, Wu T, Cheng Y, Li F, Xia W*. Celery (Apium graveolens L.) Exosome-like Nanovesicles as a New-Generation Chemotherapy Drug Delivery Platform against Tumor Proliferation. J Agri Food Chem. 2023; 71:8413-8424.
6. Cheng Y, Lu X, Li F, Chen Z, Zhang Y, Han Q, Zeng Q, Wu T, Li Z, Lu S, Williams C, Xia W*. NDFIP1 limits cellular TAZ accumulation via exosomal sorting to inhibit NSCLC proliferation. Protein Cell. 2023;14:123-136.
7. Han Q, Xie QR, Li F, Cheng Y, Wu T, Zhang Y, Lu X, Wong AST, Sha J*, Xia W*. Targeted inhibition of SIRT6 via engineered exosomes impairs tumorigenesis and metastasis in prostate cancer. Theranostics. 2021;11:6526-6541.
8. Yang X, Zhang Y, Geng K, Yang K, Shao J, Xia W*. Sirt3 protects against ischemic stroke injury by regulating HIF-1α/VEGF signaling and blood–brain barrier integrity. Cell Mol Neurobiol. 2021;41: 1203-1215.
9. Li F, Li Z, Han Q, Chen Y, Ji W, Yang Y, Lu S, Xia W*. Enhanced autocrine FGF19/FGFR4 signaling drives the progression of lung squamous cell carcinoma, which responds to mTOR inhibitor AZD2104. Oncogene. 2020; 37:3507–3521.
10. Cheng Y, Zeng Q, Han Q, Xia W*. Effect of pH, temperature and freezing-thawing on quantity changes and cellular uptake of exosomes. Protein Cell. 2019; 10:295-299.
11. Liu J, Liu Y, Shao J, Li Y, Qin L, Shen H, Xie Y, Xia W*, Gao WQ*. Zeb1 is important for proper cleavage plane orientation of dividing progenitors and neuronal migration in the mouse neocortex. Cell Death Differ.2019; 26:2479-2492.
12. Lu T, Li Z, Yang Y, Ji W, Yu Y, Niu X, Zeng Q, Xia W*, Lu S*. The Hippo/YAP1 pathway interacts with FGFR1 signaling to maintain stemness in lung cancer. Cancer Lett. 2018; 423:36-46.
13. Wang K, Ji W, Yu Y, Li Z, Niu X, Xia W*, Lu S*. FGFR1-ERK1/2-SOX2 axis promotes cell proliferation, epithelial-mesenchymal transition, and metastasis in FGFR1-amplified lung cancer. Oncogene. 2018; 37:5340-5354.
14. Shao J, Yang X, Liu T, Zhang T, Xie QR, Xia W*. Autophagy induction by SIRT6 is involved in oxidative stress-induced neuronal cell death. Protein Cell. 2016, 7:281-290. 
15. Chen Y, Gu H*, Zhang DS, Li F, Liu T, Xia W*.Highly effective inhibition of lung cancer growth and metastasis by systemic delivery of siRNA via multimodal mesoporous silica-based nanocarrier. Biomaterials. 2014;35:10058-10069.
16. Xie QR, Liu Y, Shao J, Yang J, Liu T, Zhang T, Wang B, Mruk DD, Silvestrini B, Cheng CY, Xia W*. Male contraceptive Adjudin is a potential anti-cancer drug.  Biochem Pharmacol 2013; 85:345-355.